Abstracts tagged "pulmonary fibrosis and systemic sclerosis"

Abstract Number: 1105 • 2018 ACR/ARHP Annual Meeting
Abatacept Is Effective in Experimental Digestive and Lung Tissue Fibrosis
Gonçalo Boleto¹, Christophe Guignabert², Sonia Pezet³, Anne Cauvet³, Jérémy Sadoine⁴, Ly Tu², Carole Nicco³, Camille Gobeaux⁵, Frederic Batteux³, Yannick Allanore³ and Jérôme Avouac¹, ¹Université Paris Descartes, Sorbonne Paris Cité, Service de Rhumatologie A, Hôpital Cochin, Paris, France, Paris, France, ²INSERM UMR_S 999, Le Plessis-Robinson, France, Le Plessis-Robinson, France, ³Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France, Paris, France, ⁴EA 2496 Pathologie, Imagerie et Biothérapies Orofaciales, UFR Odontologie, Université Paris Descartes and PIDV, PRES Sorbonne Paris Cité, Montrouge, France, Montrouge, France, ⁵Clinical Chemistry Laboratory, Cochin and Hôtel-Dieu Hospitals, Paris, France, Paris, France
Background/Purpose: A previous report showed that abatacept (IgG-CTLA-4) prevented and induced regression of inflammation-driven dermal fibrosis in two different mouse models of systemic sclerosis (SSc)…
Abstract Number: 2936 • 2018 ACR/ARHP Annual Meeting
Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis
Silvia Laura Bosello¹, Enrico De Lorenzis¹, Gerlando Natalello², Giovanni Battista Canestrari¹, Laura Gigante¹, Lucrezia Verardi¹, Ludovica Berardini³ and Elisa Gremese¹, ¹Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Rhematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ³Division of Respiratory Medicine, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in Systemic Sclerosis (SSc) but its pathogenesis is not fully understood. Esophageal disease is…
Abstract Number: 807 • 2016 ACR/ARHP Annual Meeting
A Novel Multi-Network Approach Reveals Tissue-Specific Cellular Modulators of Fibrosis in Systemic Sclerosis, Pulmonary Fibrosis and Pulmonary Arterial Hypertension
Jaclyn N. Taroni¹, Casey S. Greene², Tammara A. Wood³, Romy B. Christmann⁴, Harrison W. Farber⁵, Robert A. Lafyatis⁶, Christopher Denton⁷, Monique Hinchcliff⁸, Patricia A. Pioli⁹, Michael L. Whitfield¹⁰ and J. Matthew Mahoney¹¹, ¹Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, ³Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Division of Rheumatology, Boston University Medical School, Boston, MA, ⁵Pulmonary Center, Boston University Medical Center, Boston, MA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁸Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁹Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, ¹⁰Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ¹¹Department of Neurological Sciences, College of Medicine, University of Vermont, Burlington, VT
Background/Purpose: Systemic sclerosis (SSc) is characterized by multi-organ involvement and clinical heterogeneity. “Big data” approaches have yielded powerful tools to infer tissue-specific pathobiology. Large amounts of…
Abstract Number: 843 • 2016 ACR/ARHP Annual Meeting
Forced Vital Capacity Predicts Outcome in Scleroderma Associated Interstitial Lung Disease with Concomitant Pulmonary Hypertension: Data from the Pharos Registry
Joyce Sujin Lee¹, Jessica K. Gordon², Jackie Szymonifka³, Virginia Steen⁴ and Aryeh Fischer⁵, ¹SOM-MED, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Georgetown University School of Medicine, Washington, DC, ⁵Medicine / Center for Lungs and Breathing, University of Colorado School of Medicine, Aurora, CO
Forced vital capacity predicts outcome in scleroderma associated interstitial lung disease with concomitant pulmonary hypertension: Data from the PHAROS registry Background/Purpose: Interstitial lung disease…
Abstract Number: 1077 • 2015 ACR/ARHP Annual Meeting
High Levels of CCL-18 Are Associated with Deterioration of Lung Function, Increased Annual Fibrosis Progression Rate and Decreased Survival in Systemic Sclerosis
Anna-Maria Hoffmann-Vold^1,2, Anders Heiervang Tennøe², Oyvind Midtvedt¹, Torhild Garen³, May Brit Lund⁴, Trond Mogens Aalokken⁵, Cathrine Brunborg⁶, Thor Ueland² and Øyvind Molberg⁷, ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Institute of clinical medicine, University of Oslo, Oslo, Norway, ³Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Respiratory Diseases, Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway, ⁶Biostatistics, Epidemiology and Health Economics, Oslo University Hospital, Oslo, Norway, ⁷Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but biomarkers for individual risk stratification are largely missing. There is an…
Abstract Number: 2375 • 2015 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Patients with Anti-PM-Scl Antibody
Hiromichi Tamaki¹, Ruchi Yadav², James Bena³ and Soumya Chatterjee⁴, ¹Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, ²Diagnostic Radiology, Cleveland Clinic, Cleveland, OH, ³Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Patients with anti-PM-Scl antibody (PM-Scl) can present with several different phenotypes: polymyositis (PM), dermtomyositis (DM), systemic sclerosis (SSc), scleromyositis, or sclero-dermatomyositis. Interstitial Lung Disease…
Abstract Number: 2985 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Systemic Sclerosis (SSc) Patients with a Designation of Elevated Systolic Pulmonary Artery Pressure (sPAP): Forced Vital Capacity (FVC), Outcomes and Survival from the European Scleroderma Trials and Research (EUSTAR) Database
Lesley Ann Saketkoo¹, Dörte Huscher², Christopher P. Denton³, Gabriela Riemekasten⁴, Virginia D. Steen⁵, Oliver Distler⁶ and EUSTAR member centres, ¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Clinic of Rheumatology, University of Luebeck, Lübeck, Germany, ⁵Rheumatology, Georgetown University Medical Center, Washington, DC, ⁶Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland
Background/Purpose : SSc related PH carries a high mortality; with SSc-PH related to restrictive lung disease (RLD) having worse prognosis and more rapid time to…
Abstract Number: 1685 • 2014 ACR/ARHP Annual Meeting
Effects of Mycophenolate Mofetil on Pulmonary Lung Function in Interstitial Lung Disease of Systemic Sclerosis
Michael Pham¹ and W Leroy Griffing², ¹Division of Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, ²Division of Rheumatology, Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Interstitial lung disease remains a primary driver of morbidity and mortality in patients suffering from systemic sclerosis. Cyclophosphamide currently is the treatment with the…
Abstract Number: 743 • 2014 ACR/ARHP Annual Meeting
Outcome of Patients with Systemic Sclerosis Admitted to the Intensive Care Unit
Tarik Hissem¹, Alice Berezne², David Grimaldi³, Alain Cariou¹, Julien Charpentier¹, Jean-Daniel Chiche¹, Yannick Allanore⁴, Jean-Paul Mira¹, Frédéric Pène⁵ and Luc Mouthon⁶, ¹Intensive care unit - Cochin University Hospital, Paris, France, ²Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, ³Intensive Care Unit - Cochin University Hospital, Paris, France, ⁴Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ⁵Intensive care unit - Cochin university hospital, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Studies on the outcome of patients with systemic sclerosis (SSc) in intensive care unit (ICU) are scarce in the literature. Objective: To assess the…
Abstract Number: 724 • 2014 ACR/ARHP Annual Meeting
Moderate Decline in Forced Vital Capacity is Associated with a Poor Outcome in Systemic Sclerosis Patients
Anna-Maria Hoffmann-Vold¹, Oyvind Midtvedt², Torhild Garen³, May Brit Lund⁴, T. Mogens Aalokken⁵, Jan Tore Gran² and Oyvind Molberg⁶, ¹Department of Rheumatology, Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁴Department of Respiratory Medicine, Oslo University Hospital Rikshopitalet, Oslo, Norway, ⁵Department of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation in systemic sclerosis (SSc) and the leading cause of morbidity and mortality. Serial pulmonary function tests…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].